Irish researchers have found that aspirin may stop the spread of breast cancer.
Researchers funded by the Health Research Board and Irish Cancer Society have discovered that women who had been prescribed aspirin regularly before being diagnosed with breast cancer are less likely to have cancer that spread to the lymph-nodes than women who were not on prescription aspirin.
The study of Irish patients, published by the American Association for Cancer Research in the Journal, Cancer Research, analyses records from the National Cancer Registry Ireland (NCRI), and prescription data from the General Medical Service (GMS) pharmacy claims database.
“Our findings suggest that aspirin could play a role in reducing mortality from breast cancer by preventing the cancer spreading to nearby lymph nodes,” says Dr Ian Barron, the lead author who carried out the research at Trinity College Dublin.
“We analysed data from 2,796 women with stage I-III breast cancer.
“We found that those women prescribed aspirin in the years immediately prior to their breast cancer diagnosis were statistically significantly less likely to present with a lymph node-positive breast cancer than non-users. The association was strongest among women prescribed aspirin regularly and women prescribed higher aspirin doses. We now need to establish how and why this is the case”.
More details on the research paper are available at http://cancerres.aacrjournals.org/